NCT05068752 2024-09-19
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT00696696 2016-06-30
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
NYU Langone Health
Phase 2 Completed
NCT00114244 2015-01-14
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00837876 2014-06-25
Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00095966 2013-07-02
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00758381 2008-10-10
MAPS
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase 2 Unknown